Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer

Journal of Urology

Volumn 188, Issue 3, 2012, Pages 757-761

  Kaplan, Steven A ^a   Lee, Richard K ^a   Chung, Doreen E ^a   Te, Alexis E ^a   Scherr, Douglas S ^a   Tewari, Ash ^a   Vaughan, E Darracott ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

dutasteride; early detection of cancer; finasteride; prostate specific antigen; prostatic neoplasms

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; TUMOR VOLUME;

EID: 84864947976     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.04.111     Document Type: Article

References (26)

1. F. Rabbani, N. Stroumbakis, B.R. Kava Incidence and clinical significance of false-negative sextant prostate biopsies J Urol 159 1998 1247
2. L.A. Eskew, R.L. Bare, D.L. McCullough Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate J Urol 157 1997 199
3. J.C. Presti, J.J. Chang, V. Bhargava The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial J Urol 163 2000 163
4. P.G. Borboroglu, S.W. Comer, R.H. Riffenburgh Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies J Urol 163 2000 158
5. R.J. Babaian, A. Toi, K. Kamoi A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy J Urol 163 2000 152
6. M.A. Levine, M. Ittmann, J. Melamed Two consecutive series of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer J Urol 159 1998 471
7. D.W. Keetch, W.J. Catalona, D.S. Smith Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values J Urol 151 1994 1571
8. G.S. Merrick, S. Gutman, H. Andreini Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy Eur Urol 52 2007 715
9. S.A. Kaplan, M.A. Ghafar, M.A. Volpe PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study Urology 60 2002 464
10. T.A. Stamey, N. Yang, A.R. Hay Prostate specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909
11. H.A. Guess, G.J. Gormley, E. Stoner Effect of finasteride on prostate specific antigen: review of available data J Urol 155 1996 3
12. G.J. Gormley, J. Ng, T. Cook Effect of finasteride on prostate-specific antigen density Urology 43 1994 53
13. L.S. Marks, A.W. Partin, G.J. Gormley Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia J Urol 157 1997 2171
14. L.N. Thomas, R.C. Douglas, C.B. Lazier Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer J Urol 179 2008 147
15. R.D. Etzioni, N. Howlader, P.A. Shaw Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial J Urol 174 2005 877
16. I.M. Thompson, C. Chi, D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128
17. G.L. Andriole, D.G. Bostwick, O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192
18. G.L. Andriole, D. Bostwick, O.W. Brawley The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study J Urol 185 2011 126
19. M.R. Theoret, Y.M. Ning, J.J. Zhang The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2011 97
20. I.M. Thompson, P.J. Goodman, C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
21. N.E. Fleshner, M.S. Lucia, B. Egerdie Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet 379 2012 1103
22. P.C. Albertsen, J.A. Hanley, G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248
23. J.E. Oesterling, J. Roy, A. Agha Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride Urology 50 1997 13
24. R.J. Cote, E.C. Skinner, C.E. Salem The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels Br J Cancer 78 1998 413
25. G.L. Andriole, H.A. Guess, J.I. Epstein Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial PLESS Study Group. Proscar Long-term Efficacy and Safety Study Urology 52 1998 195
26. C.G. Roehrborn, G.L. Andriole, T.H. Wilson Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial Eur Urol 59 2011 244